Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ELCC 2025 | Invasive mediastinal re-staging after neoadjuvant therapy in NSCLC

Paul van Schil, MD, PhD, University Hospital Antwerp, Antwerp, Belgium, emphasizes the importance of restaging the mediastinum after neoadjuvant therapy for non-small cell lung cancer (NSCLC), particularly for patients with persistent N2 disease. This approach can significantly improve patient outcomes, as evidenced by studies from earlier trials such as EORTC 08941 (NCT00002623) and Intergroup 0139, and suggests that radiotherapy may be a more effective treatment option than surgical resection for patients with persistent N2 disease. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.